Insider Trading June 5, 2026 05:13 PM

Kinder Morgan Executive John Schlosser Executes Pre-Arranged Share Sale

V.P. for Terminals Offloads $196,263 Worth of Stock Under 10b5-1 Plan Amid Strong Quarterly Performance

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
KMI

John W. Schlosser, Vice President and President of Terminals at Kinder Morgan, Inc., executed a sale of 6,166 shares of Class P Common Stock on June 5, 2026. The transaction, valued at approximately $196,263, was conducted under a pre-arranged 10b5-1 trading plan established in May 2025. This sale follows a period of robust financial performance for the energy infrastructure company, which recently reported significant earnings and revenue beats for the first quarter of 2026.

Kinder Morgan Executive John Schlosser Executes Pre-Arranged Share Sale
KMI
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • John Schlosser sold 6,166 shares totaling approximately $196,263 under a 10b5-1 plan adopted in May 2025.
  • Kinder Morgan reported Q1 2026 EPS of $0.48 versus $0.39 expected, with revenue of $4.83 billion against $4.63 billion projected.
  • Jefferies lowered its price target to $34 from $36, citing strong EBITDA performance but maintaining a Hold rating.
John W. Schlosser, serving as Vice President and President of Terminals at Kinder Morgan, Inc. (NYSE: KMI), has executed a transaction involving the sale of 6,166 shares of the company's Class P Common Stock. The trades were completed on June 5, 2026, resulting in total proceeds of approximately $196,263. The shares were divested at prices fluctuating between $31.64 and $31.90 per share. The weighted average price for these transactions was recorded at $31.83. These sales were facilitated through a pre-arranged 10b5-1 trading plan, a mechanism designed to allow insiders to trade company stock during periods when they might otherwise be restricted. Schlosser initially adopted this specific trading plan on May 7, 2025. Following the completion of these direct sales, Schlosser's direct holdings in Kinder Morgan, Inc. Class P Common Stock stand at 170,374 shares. The execution of this sale occurs while KMI stock is trading near the $31.68 mark. The stock has demonstrated considerable momentum over the past year, posting a 17.5% gain year-to-date. According to data from InvestingPro, the current valuation suggests the stock may be slightly overvalued relative to its Fair Value estimate, a factor that places it among companies categorized on the Most Overvalued list. Despite this valuation metric, the company maintains a dividend yield of 3.75% and retains a "GOOD" financial health score. The insider transaction takes place against a backdrop of positive corporate results. Kinder Morgan Inc. recently reported financial outcomes for the first quarter of 2026 that surpassed analyst expectations. The company reported earnings per share (EPS) of $0.48, a significant improvement over the projected $0.39. This performance marked a 23.08% earnings surprise. Revenue also exceeded forecasts, reaching $4.83 billion against anticipated figures of $4.63 billion. Corporate governance updates were also noted during the 2026 Annual Meeting of Stockholders, where shareholders elected eleven directors to serve until the 2027 meeting. This governance continuity aligns with strategic financial positioning. Analyst activity surrounding the stock reflects a nuanced view of the company's trajectory. Jefferies recently adjusted its price target for Kinder Morgan shares downward to $34 from $36, while maintaining a Hold rating. The firm acknowledged the company's strong operational performance, citing a 10.2% increase in adjusted EBITDA compared to Jefferies' own estimates and a 10.6% rise against Street consensus. Furthermore, Kinder Morgan provided preliminary indications of fiscal year 2026 EBITDA upside of approximately 3% above budget. These developments highlight the company's solid financial footing and ongoing strategic decisions within the energy infrastructure sector. Investors monitoring Kinder Morgan may observe the interplay between executive trading activity and strong fundamental performance. The sale by Schlosser, executed under a pre-determined plan, stands in contrast to the positive earnings surprises and revenue growth reported in Q1 2026. The stock's current trading range near $31.68, combined with its 17.5% year-to-date gain, suggests active market interest. However, valuation metrics from InvestingPro indicate potential overvaluation relative to fair value estimates. The company's dividend yield of 3.75% and "GOOD" financial health score provide a baseline of stability. Analyst adjustments by Jefferies, including the lowered price target to $34, reflect a cautious but acknowledging stance on the company's strong EBITDA performance. The early indication of fiscal year 2026 EBITDA upside of approximately 3% above budget further underscores the operational strength within the energy infrastructure market. The transaction reflects standard executive compensation and liquidity management within the context of Kinder Morgan's broader financial results. The company's ability to exceed EPS and revenue forecasts demonstrates operational efficiency. The election of eleven directors at the annual meeting ensures governance continuity. The stock's performance and valuation metrics require careful consideration by market participants.

Risks

  • InvestingPro analysis suggests KMI stock is slightly overvalued compared to its Fair Value estimate, placing it on the Most Overvalued list.
  • Jefferies adjusted its price target downward from $36 to $34, indicating a more cautious outlook despite acknowledging strong operational metrics.

More from Insider Trading

Rocket Lab Director Slusky Offloads $4.94M in Equity Amid Sector Valuation Debate Jun 5, 2026 Xeris Biopharma Director Marla Persky Executes Strategic Share Transactions Amidst Financial Momentum Jun 5, 2026 Getty Images Executive Offloads Shares Amidst Merger Uncertainty and Earnings Miss Jun 5, 2026 Datadog Director Dev Ittycheria Offloads $34.3 Million in Shares Amid Strong Stock Performance Jun 5, 2026 Xeris Biopharma Director John Johnson Executes Share Transactions Amidst Strong Quarterly Performance Jun 5, 2026